StephenLaneRicheyMDMPH, FACP
Oncology • Fort Worth, TXHematology Oncology Consultant Phase I Research Fort Worth, US Oncology Translational Research Program
Dr. Richey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
500 S Henderson St
Ste 200
Fort Worth, TX 76104Phone+1 817-413-1500Fax+1 817-413-1499
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2004 - 2007
Louisiana State University School of Medicine in New OrleansClass of 2004
Certifications & Licensure
TX State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
- A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
- Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsA phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients wit...Vandana G Abramson, Mafalda Oliveira, Andrés Cervantes, Hans Wildiers, Manish R. Patel
Breast Cancer Research and Treatment. 2019-07-31 - 45 citationsA randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, J.-L. Lee, Bhumsuk Keam
Annals of Oncology. 2017-11-01 - 25 citationsA Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell CarcinomaSumanta K. Pal, Arun Azad, Shailender Bhatia, Harry A. Drabkin, Brian A. Costello
Clinical Cancer Research. 2015-08-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
